EMERGE母婴研究:二甲双胍治疗GDM后母子长期队列随访方案
本研究为前瞻性观察性纵向队列随访,纳入既往EMERGE随机安慰剂对照试验中患妊娠期糖尿病的母亲及其子女,计划最多321对母子在指数妊娠后6年内进行单次随访。主要评估母亲心脏代谢健康及儿童人体测量与神经发育结局,以补充二甲双胍孕期使用长期安全性证据。
要点
- 随访EMERGE试验中GDM母亲及其子女,评估二甲双胍长期安全性。
- 计划最多321对母子,指数妊娠后6年内单次随访。
- 母亲评估代谢指标,儿童评估生长、脂肪及神经发育。
核心结论
- 旨在评估GDM母亲孕期使用二甲双胍后母子长期心脏代谢、人体测量及神经发育结局。
研究设计与样本
- 前瞻性观察性纵向队列随访研究,纳入既往EMERGE随机安慰剂对照试验的GDM母亲及其子女。
- 单中心医院临床研究场所,计划便利样本最多321对母子,指数妊娠后6年内单次随访。
关键数值与推荐
- 纳入标准为参与过EMERGE试验并同意随访的母亲及其子女。
- 排除标准为未同意参加未来随访研究者。
- 母亲评估包括人体测量、糖耐量及代谢参数;儿童评估包括生长指标、皮褶厚度测脂肪及验证问卷评神经发育。
临床怎么用
- 为临床咨询GDM孕期二甲双胍使用的长期母子安全性提供前瞻性队列证据。
局限性
- 采用便利抽样,单中心随访,可能存在选择偏倚与随访依从性限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pregnancies complicated by gestational diabetes mellitus (GDM) are associated with increased risks of adverse perinatal outcomes and with long-term metabolic and cardiovascular consequences for both mother and child. The original EMERGE randomized controlled trial (RCT) evaluated the effectiveness of early metformin in addition to usual care in women with GDM on glycemic control and perinatal outcomes. The primary objective of the EMERGE Mothers and Kids study is to evaluate long-term maternal cardiometabolic health and child anthropometric and neurodevelopmental outcomes following participation in the EMERGE trial. METHODS: This is a prospective, observational longitudinal cohort follow-up study of women and their children previously enrolled in the EMERGE trial (NCT06327191). Participants are invited to attend a follow-up visit in a single-site hospital-based clinical research setting at the Clinical Research Facility Galway, Ireland. Key inclusion criteria are women and their children who participated in the EMERGE trial and consent to follow-up. Key exclusion criteria include participants who did not provide consent for future follow-up studies. The planned follow-up sample is a pragmatic convenience sample of up to 321 mother-child pairs. A single follow-up visit will be conducted up to 6 years after the index pregnancy. Maternal assessments include anthropometric data, glucose tolerance, and metabolic parameters. Child assessments include growth metrics, adiposity measured via skinfold thickness, and neurodevelopmental status assessed through validated questionnaires. Additional data on quality of life, mental health, breastfeeding, and health economics will also be collected. DISCUSSION: This study aims to provide insights into the long-term safety and efficacy of metformin use during pregnancy, addressing the evidence gap in maternal cardiometabolic outcomes after metformin-treated GDM while also assessing child anthropometric and neurodevelopmental outcomes. TRIAL REGISTRATION: ClinicalTrials.gov NCT06327191. Registered on November 21, 2023. First planned enrollment in this follow-up study: July 2024. Trial record available at https://clinicaltrials.gov/study/NCT06327191 .
引用
- Scairati R, Newman C, Alvarez-Iglesias A, et al. EMERGE Mothers and Kids: a longitudinal cohort study of mothers and children enrolled in the randomized placebo-controlled trial of metformin in women with GDM (EMERGE): study protocol. Trials. 2026. PMID: 42010697. doi:10.1186/s13063-026-09703-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。